Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
5.120 ^USD	+0.39%		-8.90%	-16.75%

Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM

Analyst Reco.

Nov. 04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
25-08-07	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
25-08-06	Top Midday Gainers	MT
25-05-21	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
25-05-21	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT
25-05-19	Morgan Stanley Cuts Price Target on Myriad Genetics to $7 From $16, Maintains Equalweight Rating	MT
25-05-08	Wolfe Research Downgrades Myriad Genetics to Peer Perform From Outperform	MT
25-05-07	UBS Adjusts Price Target on Myriad Genetics to $7 From $16, Maintains Neutral Rating	MT
25-05-07	Wells Fargo Downgrades Myriad Genetics to Equalweight From Overweight, Adjusts Price Target to $6 From $22	MT
25-04-09	Guggenheim Downgrades Myriad Genetics to Neutral From Buy	MT
25-03-12	Myriad Genetics Shares Rise After Upgrade From Piper Sandler	MT
25-03-12	Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50	MT
25-02-25	UBS Adjusts Price Target on Myriad Genetics to $16 From $18, Maintains Neutral Rating	MT
24-12-09	Leerink Partners Downgrades Myriad Genetics to Market Perform From Outperform, Cuts Price Target to $21 From $30	MT
24-11-18	Morgan Stanley Cuts Price Target on Myriad Genetics to $21 From $32, Keeps Equalweight Rating	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight With $32 Price Target	MT
24-09-19	Morgan Stanley Initiates Myriad Genetics at Equalweight	MT
24-08-28	Wells Fargo Initiates Myriad Genetics at Overweight With $35 Price Target	MT
24-06-27	Scotiabank Initiates Myriad Genetics at Sector Outperform	MT
24-05-13	Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating	MT
24-01-29	Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	MT
24-01-29	BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	MT
23-12-19	Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	MT
23-12-13	Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	MT
23-10-20	BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Analyst Reco.

Filters